Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Institute for Exposomic Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
EBioMedicine. 2023 Nov;97:104831. doi: 10.1016/j.ebiom.2023.104831. Epub 2023 Oct 24.
Although per- and polyfluoroalkyl substances (PFAS) exposure is a potential contributor to the increasing thyroid cancer trend, limited studies have investigated the association between PFAS exposure and thyroid cancer in human populations. We therefore investigated associations between plasma PFAS levels and thyroid cancer diagnosis using a nested case-control study of patients with thyroid cancer with plasma samples collected at/before cancer diagnosis.
88 patients with thyroid cancer using diagnosis codes and 88 healthy (non-cancer) controls pair-matched on sex, age (±5 years), race/ethnicity, body mass index, smoking status, and year of sample collection were identified in the BioMe population (a medical record-linked biobank at the Icahn School of Medicine at Mount Sinai in New York); 74 patients had papillary thyroid cancer. Eight plasma PFAS were measured using untargeted analysis with liquid chromatography-high resolution mass spectrometry and suspect screening. Associations between individual PFAS levels and thyroid cancer were evaluated using unconditional logistic regression models to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI).
There was a 56% increased rate of thyroid cancer diagnosis per doubling of linear perfluorooctanesulfonic acid (n-PFOS) intensity (OR, 1.56, 95% CI: 1.17-2.15, P = 0.004); results were similar when including patients with papillary thyroid cancer only (OR, 1.56, 95% CI: 1.13-2.21, P = 0.009). This positive association remained in subset analysis investigating exposure timing including 31 thyroid cancer cases diagnosed ≥1 year after plasma sample collection (OR, 2.67, 95% CI: 1.59-4.88, P < 0.001).
This study reports associations between exposure to PFAS and increased rate of (papillary) thyroid cancer. Thyroid cancer risk from PFAS exposure is a global concern given the prevalence of PFAS exposure. Individual PFAS studied here are a small proportion of the total number of PFAS supporting additional large-scale prospective studies investigating thyroid cancer risk associated with exposure to PFAS chemicals.
National Institutes of Health grants and The Andrea and Charles Bronfman Philanthropies.
尽管全氟和多氟烷基物质(PFAS)暴露可能是甲状腺癌发病率上升的一个潜在因素,但有限的研究调查了人群中 PFAS 暴露与甲状腺癌之间的关联。因此,我们使用甲状腺癌患者的病例对照嵌套研究,对癌症诊断前/时采集的血浆样本进行了分析,以调查血浆 PFAS 水平与甲状腺癌诊断之间的关联。
在纽约西奈山伊坎医学院的生物医学人群(一个与医疗记录相关的生物库)中,使用诊断代码识别了 88 例甲状腺癌患者和 88 例健康(非癌症)对照(按性别、年龄(±5 岁)、种族/族裔、体重指数、吸烟状况和样本采集年份匹配);74 例患者患有甲状腺乳头状癌。使用液相色谱-高分辨质谱联用仪和可疑筛查进行非靶向分析,检测了 8 种血浆 PFAS。使用非条件逻辑回归模型评估个体 PFAS 水平与甲状腺癌之间的关联,以估计调整后的比值比(OR)和 95%置信区间(CI)。
全氟辛烷磺酸(n-PFOS)强度每增加一倍,甲状腺癌诊断率增加 56%(OR,1.56,95%CI:1.17-2.15,P=0.004);当包括仅患有甲状腺乳头状癌的患者时,结果相似(OR,1.56,95%CI:1.13-2.21,P=0.009)。当包括包括 31 例癌症诊断≥1 年的病例的暴露时间亚组分析时,该正相关仍然存在(OR,2.67,95%CI:1.59-4.88,P<0.001)。
本研究报告了 PFAS 暴露与(甲状腺乳头状)甲状腺癌发病率增加之间的关联。鉴于 PFAS 暴露的普遍性,PFAS 暴露引起的甲状腺癌风险是一个全球性的关注问题。这里研究的单个 PFAS 只是 PFAS 化学物质总数量的一小部分,支持进行更多的大规模前瞻性研究,以调查 PFAS 暴露与甲状腺癌风险之间的关系。
美国国立卫生研究院拨款和安德烈和查尔斯·布朗夫曼慈善基金会。